In this issue:
Durable remissions with ivosidenib in IDH1-mutated R/R AML
ASCT vs alloHSCT in early treatment failure follicular lymphoma
AML: Somatic mutations clearance at remission and relapse risk
Diagnosis-to-treatment interval in DLBCL
EURO-SKI: Discontinuation of TKI in CML
First-line gemcitabine-oxaliplatin + rituximab in elderly DLBCL
Polygenic risk score and risk of CLL ctDNA insights in classical Hodgkin lymphoma
Moxetumomab pasudotox and hairy cell leukaemia
Burkitt lymphoma treated with CODOX-M/IVAC +/- rituximab
Please login below to download this issue (PDF)